1-6 of 6
Mark Douglas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Clinical Trials & Observations
Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison Moskowitz, Megan Perez, Patricia Myskowski, Adam Officer, Jacob D. Jaffe, Sara N. Morrow, Kerstin Allen, Mark Douglas, Howard Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C. Aster, David Weaver, Francine M. Foss, David M. Weinstock
Journal: Blood
Blood (2018) 131 (8): 888–898.
https://doi.org/10.1182/blood-2017-08-802470
Published: 2018
Includes: Supplemental data
Journal Articles

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Clinical Trials & Observations
Ian W. Flinn, Susan O’Brien, Brad Kahl, Manish Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey Jones, Jan A. Burger, Nitin Jain, Virginia M. Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven Horwitz
Journal: Blood
Blood (2018) 131 (8): 877–887.
https://doi.org/10.1182/blood-2017-05-786566
Published: 2018
Includes: Supplemental data
Journal Articles

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Ian Flinn, Yasuhiro Oki, MD, Manish Patel, Steven M. Horwitz, MD, Francine M. Foss, MD, Jennifer Sweeney, Kerstin Allen, MA, Mark Douglas, MS, Lori Steelman, Joi Dunbar, PharmD, Howard M. Stern, MD PhD, Patrick Kelly, MD, Brad Kahl, MD
Journal: Blood
Blood (2014) 124 (21): 802.
https://doi.org/10.1182/blood.V124.21.802.802
Published: 2014
Journal Articles

Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma

Steven M. Horwitz, MD, Pierluigi Porcu, MD, Ian Flinn, Brad S. Kahl, MD, Jennifer Sweeney, Howard M. Stern, MD PhD, Mark Douglas, MS, Kerstin Allen, MA, Patrick Kelly, MD, Francine M. Foss, MD
Journal: Blood
Blood (2014) 124 (21): 803.
https://doi.org/10.1182/blood.V124.21.803.803
Published: 2014
Journal Articles

Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ

Marisa Peluso, MS, Kerrie Faia, MS, David Winkler, PhD, Nidhi Patel, MS, Erin Brophy, BS, Kerry White, BA, Mark Douglas, MS, Howard M. Stern, MD PhD, Vito Palombella, PhD, Karen McGovern, PhD, Jeffery L. Kutok, MD PhD
Journal: Blood
Blood (2014) 124 (21): 328.
https://doi.org/10.1182/blood.V124.21.328.328
Published: 2014
Journal Articles

Treatment With The Potent PI3K-δ,γ Inhibitor IPI-145 Is Associated With Rapid Decreases In Specific Cytokines, Chemokines and Matrix Metalloproteinases In The Serum Of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

Mark Douglas, M.S., Ken Allison, M.S., Synder Ted, B.A., Kerstin Allen, MA, Brad S. Kahl, MD, Steven M. Horwitz, MD, Ian W. Flinn, MD, PhD, Patrick Kelly, MD, Howard M. Stern, M.D., Ph.D
Journal: Blood
Blood (2013) 122 (21): 1633.
https://doi.org/10.1182/blood.V122.21.1633.1633
Published: 2013